A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

Exclusion Criteria

• •1. Patients receiving any other investigational agents
• •2. Previous treatment with anti-EGF-R drug(s)
• •3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to nimotuzumab or other agents used in study.
• •4. Prior thoracic radiotherapy for this condition
• •5. Prior chemotherapy within 4 weeks of enrolment
• •6. Lesions not suitable for radiotherapy
• •7. Patients with known sero positive HIV
• •8. Patients with uncontrolled hypercalcemia
• •9. Patients with progressive or untreated brain metastases or treated brain metastases but unable to discontinue steroids
• •10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, severe cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator
• •11. Pregnant or breast-feeding women
• •12. Any concurrent active malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix; patients with other prior malignancies are eligible providing prior malignancy cannot be clinically confused with the diagnosis of NSCLC in the opinion of the treating oncologist; in particular, there should be no evidence of current disease activity with respect to the prior malignancy
• •13. Life expectancy of less than 8 weeks